EP0017

**EP0017** is a first-in-class bifunctional fusion protein developed initially by SunRock Biopharma and exclusively licensed to Ellipses Pharma for global development. It features a dual mechanism of action, selectively targeting **HER3** (human epidermal growth factor receptor 3), which is overexpressed in various tumor types, while simultaneously binding to death receptors **DR4** and **DR5** to induce tumor cell apoptosis via the TRAIL pathway. Preclinical data demonstrate promising antitumor activity across multiple models, positioning it as a novel immunotherapy for HER3-expressing cancers, with Ellipses planning clinical trials and potential out-licensing for commercialization.[1][2][3]